Additional Transfer Sample Clauses
The Additional Transfer clause defines the conditions under which assets, rights, or obligations beyond those initially specified may be transferred between parties. Typically, this clause outlines the process for identifying, approving, and documenting any such additional transfers, and may specify limitations or requirements, such as notice periods or consent from both parties. Its core practical function is to provide a clear mechanism for handling unforeseen or supplementary transfers, thereby ensuring flexibility and reducing the risk of disputes over future asset movements.
Additional Transfer. If any Purchased Patent is subject to a Disclaimer Issue after the Effective Date with respect to any other patent or patent application of Seller or its Affiliates, Seller shall transfer, and hereby does transfer, ownership of such patent or patent application to Purchaser without additional consideration and such patent or patent application shall be a Purchased Patent.
Additional Transfer. During the Term, in the event that Context reasonably believes additional BioAtla Know-How is necessary for the continued Exploitation of the Licensed Antibodies or Program Products, Context may reasonably request a copy of such additional BioAtla Know-How from BioAtla. BioAtla will transfer to Context a copy of such additional BioAtla Know-How, including any documentation (whether held in paper or electronic format) or similar removable media.
Additional Transfer. Following the initial transfer described in Section 4.3.1, Company will provide updates to Vertex [***] per [***] regarding any newly acquired or generated Licensed Know-How, including information concerning any Products or Licensed Agents, and improved procedures for synthesis or manufacture of Licensed Agents or Product. As reasonably requested by Vertex, Company will promptly provide Vertex with any specific information included in the Licensed Technology that is necessary or useful for Vertex to Exploit the Licensed Compounds or Products. Company will provide such information to Vertex within [***] after Vertex’s request.
Additional Transfer. In addition to, and within sixty (60) days following, the transfer of assets from the Abbott ARP to the Hospira ARP described in Section 4.1(b) of this Agreement, Abbott shall pay Hospira an amount equal to that amount which, if contributed by Hospira to the Hospira ARP immediately following the transfer of assets required by Section 4.1(b) of this Agreement, would cause the ABO Funded Ratio of the Hospira ARP and the Abbott ARP to be equivalent as of the Distribution Date. With respect to a plan, the ABO Funded Ratio shall equal the fair market value of assets of that plan divided by the Accumulated Benefit Obligation of that plan, as determined under FAS 87. In calculating the ABO Funded Ratio, the assets for the Hospira ARP shall include the amount transferred directly from the Abbott ARP in accordance with Section 4.1(b) of this Agreement and the amount to be paid by Abbott in accordance with this Section 4.1(c). The pro-rata share of the 2003 plan year contributions assigned to the Abbott ARP in 4.1(b), that are contributed following the Distribution Date, shall be taken into account for purposes of calculating the ABO Funded Ratio of the Abbott ARP as of the Distribution Date as if those contributions had been part of the assets of the Abbott ARP on the Distribution Date. Similarly, the pro-rata share of the 2003 plan year contributions assigned to the Hospira ARP in Section 4.1(b) of this Agreement, that are contributed following the Distribution Date, shall be taken into account for purposes of calculating the ABO Funded Ratio of the Hospira ARP as of the Distribution Date as if those contributions had been part of the assets of the Hospira ARP on the Distribution Date. With the exception of the discount rate, the Accumulated Benefit Obligation shall be calculated using the assumptions and methodology used to calculate ▇▇▇▇▇▇'▇ December 31, 2003, FAS 87 disclosure information. The discount rate shall be determined as of the Distribution Date using ▇▇▇▇▇▇'▇ FAS 87 discount rate setting methodology consistent with ▇▇▇▇▇▇'▇ past practices. Hospira shall not be required to reimburse Abbott for any tax benefit received by Hospira with respect to any contribution to the Hospira ARP.
Additional Transfer. Notwithstanding any other provision of this Agreement, no Transfer of Subordinated Notes or of Warrants shall be effected unless any Transfer of Subordinated Notes is accompanied by a Transfer (to the same transferee) of Warrants having an aggregate Warrant Exercise Price (as defined in the Warrant Instrument) equal to the aggregate principal amount of the Subordinated Notes the subject of the Transfer, and vice versa.
Additional Transfer. The Seller agree transfer additional equity interest/ownership of Ticode to the Buyer as follows:
i. If Ticode does not achieve an Earnings Before Interest and Taxes (the “EBIT”) for at least ▇▇▇ ▇▇ million for the fiscal year ended December 31, 2021 (the “2021 EBIT Goal”) as evidenced by the financial statements of Ticode audited by the auditor of the Company, the Seller shall transfer an additional 5% of the equity interest/ownership of Ticode to Buyer at no cost within 30 days of the date of the 2021 audit report; and
ii. If Ticode does not achieve an EBIT for at least RMB 57.5 million for the fiscal year ended December 31, 2022 (the “2022 EBIT Goal”) as evidenced by the financial statements of Ticode audited by the auditor of the Company, the Seller shall further transfer an additional 5% of the equity interest/ownership of Ticode to Buyer at no cost within 30 days of the date of the 2022 audit report; and